TRANSGENIC PRODUCTION OF HEPARIN

• US 20160326547A1
• Filed: 12/19/2014
• Published: 11/10/2016
• Est. Priority Date: 12/24/2013
• Status: Abandoned Application

• Current Assignee: LFB USA, Inc. (Agence des Participations de l’Etat)
• Original Assignee: LFB USA, Inc. (Agence des Participations de l’Etat)
• Inventors: Meade, Harry M., Gavin, William G.
• Application Number:
  US15/108,061
• Publication Number:
  US 20160326547A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A01K 2217/15 Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
• CPC Class Codes: A01K 2227/101 Bovine
• CPC Class Codes: A01K 2227/102 Caprine
• CPC Class Codes: A01K 2267/02 Animal zootechnically ameliorated
• CPC Class Codes: A01K 67/0275 Genetically modified vertebrates, e.g. transgenic
• CPC Class Codes: A61K 31/727 Heparin; Heparan
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: C12N 15/8509 for producing genetically modified animals, e.g. transgenic
• CPC Class Codes: C12N 2015/8518 expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
• CPC Class Codes: C12P 19/26 Preparation of nitrogen-containing carbohydrates

Abstract

The disclosure provides methods, cells and transgenic non human mammals for the production of heparin. Specifically, the method comprising providing a transgenic non human mammal or mammary epithelial cells modified to express one or more heparin biosynthesis enzymes, and harvesting heparin produced. Further provided are the cells and transgenic non human mammals thereof as well as the heparin obtained from these cells or transgenic non human mammals.

Claims

1. A method of producing heparin, the method comprising

providing a non human transgenic mammal that produces heparin in its milk, and

harvesting heparin from the milk produced by the mammary gland of the transgenic mammal.

4. The method of any one of claims 1-3, wherein the transgenic mammal is an ungulate.

5. The method of claim 4, wherein the ungulate is a goat.

6. The method of claim 5, wherein the ungulate is a bovine.

12. A transgenic non human mammal as defined in any one of the preceding claims.

15. The method, mammal or cells of any one of the preceding claims, wherein one or more of the heparin biosynthesis enzymes are under the control of a milk promoter.

16. The method, mammal or cells of claim 15, wherein the milk promoter is a goat beta casein promoter.

17. Heparin produced according to any of the methods of the preceding claims.

18. A composition comprising the heparin of claim 17.

19. The composition of claim 18, further comprising milk.

2. A method of producing heparin, the method comprising

providing a non human transgenic mammal that has been modified to express one or more heparin biosynthesis enzymes in the mammary gland, and

harvesting heparin from the milk produced by the mammary gland of the transgenic mammal.

3. A method of producing heparin, the method comprising

providing a non human transgenic mammal that has been modified to express one or more heparin biosynthesis enzymes and core protein in the mammary gland, and

harvesting heparin from the milk produced by the mammary gland of the transgenic mammal.

7. A method of producing heparin, the method comprising

providing mammary epithelial cells that have been modified to express one or more heparin biosynthesis enzymes, and

harvesting heparin from the mammary epithelial cells.

8. A method of producing heparin, the method comprising

providing mammary epithelial cells that have been modified to express one or more heparin biosynthesis enzymes and core protein, and

harvesting heparin from the mammary epithelial cells.

9. A transgenic non human mammal that produces heparin in its milk.

10. A transgenic non human mammal that has been modified to express one or more heparin biosynthesis enzymes in its mammary gland.

11. A transgenic non human mammal that has been modified to express one or more heparin biosynthesis enzymes and core protein in its mammary gland.

13. Mammary epithelial cells that have been modified to express one or more heparin biosynthesis enzymes.

14. Mammary epithelial cells that have been modified to express one or more heparin biosynthesis enzymes and core protein.